Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study

Table 1 Distribution of the analyzed parameters in the whole population

Distribution of the four analyzed parameters potentially affecting PBSC collection in 1,348 newly diagnosed myeloma patients. Lenalidomide use: up to four cycles; baseline cytopenia: Hb <10 g/dl, neutrophil count <1 × 10⁹/L, platelet count <100 × 10⁹/L: at least one at diagnosis; hematological toxicity: grade 3 or 4 during induction therapy (CTCAE v4). PBSC, peripheral blood stem cells.

ISSN: 1757-6512